A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation

Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC drug resistance. Unlike irreversible gene mutations, epigenetic changes are r...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2024-07, Vol.176, p.116902, Article 116902
Main Authors: Su, Xiaorui, Li, Yuxuan, Ren, Yupeng, Cao, Mingbo, Yang, Gaoyuan, Luo, Jing, Hu, Ziyi, Deng, Haixia, Deng, Meihai, Liu, Bo, Yao, Zhicheng
Format: Article
Language:English
Subjects:
Drug resistance
Epigenetic
Liver cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC drug resistance. Unlike irreversible gene mutations, epigenetic changes are reversible, offering a promising avenue for preventing and overcoming drug resistance in liver cancer. This review focuses on various epigenetic modifications relevant to drug resistance in HCC and their underlying mechanisms. Additionally, we introduce current clinical epigenetic drugs and clinical trials of these drugs as regulators of drug resistance in other solid tumors. Although there is no clinical study to prevent the occurrence of drug resistance in liver cancer, the development of liquid biopsy and other technologies has provided a bridge to achieve this goal.
ISSN:0753-3322
1950-6007
1950-6007
DOI:10.1016/j.biopha.2024.116902